ReviewInnovations in clinical neuroscience
Lessons Learned from Drug Development Programs in Autism: Implications for Future Programs.
Review in Innovations in clinical neuroscience. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There are no approved drugs for autism core features; the heterogeneous biology, symptom presentation, and clinical outcomes complicate drug trials design, and have hampered therapeutic drug development. We synthesized expert viewpoints from industry and academia on recent diagnostics and biomarker advances as well as pharmacotherapy evidence, aligned to patient-focused drug development outcomes and key concepts. Key learnings include: (i) measure what matters to patients and caregivers; (ii) enrich populations where they can be rationally matched to mechanism; (iii) do not use diagnostic tools as efficacy endpoints; (iv) align biomarker science with a potential qualification pathway associated with relevant behavior and biology; (v) design trials that reduce placebo response, burden, and attrition; (vi) assess co-occurring conditions and treatments explicitly. Observations and recommendations serve as a practical roadmap for sponsors and clinicians to increase trial informativeness and chance of success.
Indexed as
Identifiers
42761731PMC13588654What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.